Heterogeneity and treatment landscape of ovarian carcinoma.
Journal
Nature reviews. Clinical oncology
ISSN: 1759-4782
Titre abrégé: Nat Rev Clin Oncol
Pays: England
ID NLM: 101500077
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
04
09
2023
medline:
20
11
2023
pubmed:
3
10
2023
entrez:
2
10
2023
Statut:
ppublish
Résumé
Ovarian carcinoma is characterized by heterogeneity at the molecular, cellular and anatomical levels, both spatially and temporally. This heterogeneity affects response to surgery and/or systemic therapy, and also facilitates inherent and acquired drug resistance. As a consequence, this tumour type is often aggressive and frequently lethal. Ovarian carcinoma is not a single disease entity and comprises various subtypes, each with distinct complex molecular landscapes that change during progression and therapy. The interactions of cancer and stromal cells within the tumour microenvironment further affects disease evolution and response to therapy. In past decades, researchers have characterized the cellular, molecular, microenvironmental and immunological heterogeneity of ovarian carcinoma. Traditional treatment approaches have considered ovarian carcinoma as a single entity. This landscape is slowly changing with the increasing appreciation of heterogeneity and the recognition that delivering ineffective therapies can delay the development of effective personalized approaches as well as potentially change the molecular and cellular characteristics of the tumour, which might lead to additional resistance to subsequent therapy. In this Review we discuss the heterogeneity of ovarian carcinoma, outline the current treatment landscape for this malignancy and highlight potentially effective therapeutic strategies in development.
Identifiants
pubmed: 37783747
doi: 10.1038/s41571-023-00819-1
pii: 10.1038/s41571-023-00819-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
820-842Informations de copyright
© 2023. Springer Nature Limited.
Références
Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023).
pubmed: 36633525
doi: 10.3322/caac.21763
SEER*Explorer Application. All cancer sites combined. Recent trends in SEER age-adjusted incidence rates, 2000–2020. https://seer.cancer.gov/statistics-network/explorer/application.html?site=1&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0 (2020).
Slomovitz, B., de Haydu, C., Taub, M., Coleman, R. L. & Monk, B. J. Asbestos and ovarian cancer: examining the historical evidence. Int. J. Gynecol. Cancer 31, 122–128 (2021).
pubmed: 33037108
doi: 10.1136/ijgc-2020-001672
Vachon, C. M. et al. Association of parity and ovarian cancer risk by family history of breast or ovarian cancer in a population-based study of postmenopausal women. Epidemiol. Camb. Mass. 13, 66–71 (2002).
doi: 10.1097/00001648-200201000-00011
Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N. Engl. J. Med. 316, 650–655 (1987).
doi: 10.1056/NEJM198703123161102
Liu, Y. L. et al. Risk-reducing bilateral salpingo-oophorectomy for ovarian cancer: a review and clinical guide for hereditary predisposition genes. JCO Oncol. Pract. 18, 201–209 (2022).
pubmed: 34582274
doi: 10.1200/OP.21.00382
Permuth-Wey, J. & Sellers, T. A. Epidemiology of ovarian cancer. Cancer Epidemiol. 472, 413–437 (2009).
doi: 10.1007/978-1-60327-492-0_20
Ngoi, N. Y. L. & Tan, D. S. P. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? ESMO Open. 6, 100144 (2021).
pubmed: 34015643
pmcid: 8141874
doi: 10.1016/j.esmoop.2021.100144
Bell, D. et al. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).
doi: 10.1038/nature10166
Vázquez-García, I. et al. Ovarian cancer mutational processes drive site-specific immune evasion. Nature 612, 778–786 (2022).
pubmed: 36517593
pmcid: 9771812
doi: 10.1038/s41586-022-05496-1
Brutovský, B. Scales of cancer evolution: selfish genome or cooperating cells? Cancers 14, 3253 (2022).
pubmed: 35805025
pmcid: 9264996
doi: 10.3390/cancers14133253
Hu, Z. et al. The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells. Cancer Cell 37, 226–242.e7 (2020).
pubmed: 32049047
doi: 10.1016/j.ccell.2020.01.003
Ishak, C. A., Lheureux, S. & De Carvalho, D. D. DNA methylation as a robust classifier of epithelial ovarian cancer. Clin. Cancer Res. 25, 5729–5731 (2019).
pubmed: 31337645
doi: 10.1158/1078-0432.CCR-19-1797
Bodelon, C. et al. Molecular classification of epithelial ovarian cancer based on methylation profiling: evidence for survival heterogeneity. Clin. Cancer Res. 25, 5937–5946 (2019).
pubmed: 31142506
pmcid: 6774865
doi: 10.1158/1078-0432.CCR-18-3720
Höhn, A. K. et al. WHO classification of female genital tumors. Geburtshilfe Frauenheilkd. 81, 1145–1153 (2021). 2020.
pubmed: 34629493
pmcid: 8494521
doi: 10.1055/a-1545-4279
Prat, J., D’Angelo, E. & Espinosa, I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum. Pathol. 80, 11–27 (2018).
pubmed: 29944973
doi: 10.1016/j.humpath.2018.06.018
Peres, L. C. et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J. Natl Cancer Inst. 111, 60–68 (2019).
pubmed: 29718305
doi: 10.1093/jnci/djy071
Meinhold-Heerlein, I. et al. Statement by the kommission ovar of the AGO: the new FIGO and WHO classifications of ovarian, fallopian tube and primary peritoneal cancer. Geburtshilfe Frauenheilkd. 75, 1021–1027 (2015).
pubmed: 26556905
pmcid: 4629993
doi: 10.1055/s-0035-1558079
Hanley, G. E. et al. Outcomes from opportunistic salpingectomy for ovarian cancer prevention. JAMA Netw. Open. 5, e2147343 (2022).
pubmed: 35138400
pmcid: 8829665
doi: 10.1001/jamanetworkopen.2021.47343
Chen, S. et al. A review of the clinical characteristics and novel molecular subtypes of endometrioid ovarian cancer. Front. Oncol. 11, 668151 (2021).
pubmed: 34150634
pmcid: 8210668
doi: 10.3389/fonc.2021.668151
Zhu, C. et al. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study. BMC Cancer 21, 322 (2021).
pubmed: 33766002
pmcid: 7993454
doi: 10.1186/s12885-021-08061-7
Montag, A. G. et al. Ovarian clear cell carcinoma. A clinicopathologic analysis of 44 cases. Int. J. Gynecol. Pathol. 8, 85–96 (1989).
pubmed: 2469661
doi: 10.1097/00004347-198906000-00001
Bolton, K. L. et al. Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes. Clin. Cancer Res. 28, 4947–4956 (2022).
pubmed: 35816189
pmcid: 9777703
doi: 10.1158/1078-0432.CCR-21-3817
Lheureux, S. Multi-omics uncovering different faces of clear cell ovarian cancer. Clin. Cancer Res. 28, 4838–4839 (2022).
pubmed: 36094332
doi: 10.1158/1078-0432.CCR-22-2365
Manning-Geist, B. et al. MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. Clin. Cancer Res. 28, 4456–4465 (2022).
pubmed: 35443055
pmcid: 9582036
doi: 10.1158/1078-0432.CCR-21-4183
Veneziani, A. C. & Oza, A. M. Taking the road less traveled: following molecular trail markers. Clin. Cancer Res. 28, 4357–4359 (2022).
pubmed: 35960159
doi: 10.1158/1078-0432.CCR-22-1623
Morice, P., Gouy, S. & Leary, A. Mucinous ovarian carcinoma. N. Engl. J. Med. 380, 1256–1266 (2019).
pubmed: 30917260
doi: 10.1056/NEJMra1813254
Babaier, A. & Ghatage, P. Mucinous cancer of the ovary: overview and current status. Diagnostics 10, 52 (2020).
pubmed: 31963927
pmcid: 7168201
doi: 10.3390/diagnostics10010052
Tischkowitz, M. et al. Small-cell carcinoma of the ovary, hypercalcemic type-genetics, new treatment targets, and current management guidelines. Clin. Cancer Res. 26, 3908–3917 (2020).
pubmed: 32156746
pmcid: 7415570
doi: 10.1158/1078-0432.CCR-19-3797
McCluggage, W. G., Witkowski, L., Clarke, B. A. & Foulkes, W. D. Clinical, morphological and immunohistochemical evidence that small-cell carcinoma of the ovary of hypercalcaemic type (SCCOHT) may be a primitive germ-cell neoplasm. Histopathology 70, 1147–1154 (2017).
pubmed: 28130795
doi: 10.1111/his.13177
Bieging, K. T., Mello, S. S. & Attardi, L. D. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 14, 359–370 (2014).
pubmed: 24739573
pmcid: 4049238
doi: 10.1038/nrc3711
Ahmed, A. A. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221, 49–56 (2010).
pubmed: 20229506
pmcid: 3262968
doi: 10.1002/path.2696
Li, X. & Heyer, W.-D. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 18, 99–113 (2008).
pubmed: 18166982
doi: 10.1038/cr.2008.1
Bowtell, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15, 668–679 (2015).
pubmed: 26493647
pmcid: 4892184
doi: 10.1038/nrc4019
Kroeger, P. T. & Drapkin, R. Pathogenesis and heterogeneity of ovarian cancer. Curr. Opin. Obstet. Gynecol. 29, 26–34 (2017).
pubmed: 27898521
doi: 10.1097/GCO.0000000000000340
Etemadmoghadam, D. et al. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS ONE 5, e15498 (2010).
pubmed: 21103391
pmcid: 2980490
doi: 10.1371/journal.pone.0015498
Lheureux, S., Braunstein, M. & Oza, A. M. Epithelial ovarian cancer: evolution of management in the era of precision medicine. Ca. Cancer J. Clin. 69, 280–304 (2019).
pubmed: 31099893
doi: 10.3322/caac.21559
Veneziani, A. C., Scott, C., Wakefield, M. J., Tinker, A. V. & Lheureux, S. Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer. Ther. Adv. Med. Oncol. 15, 17588359231157644 (2023).
pubmed: 36872947
pmcid: 9983116
doi: 10.1177/17588359231157644
Matulonis, U. A. et al. Ovarian cancer. Nat. Rev. Dis. Prim. 2, 16061 (2016).
pubmed: 27558151
doi: 10.1038/nrdp.2016.61
Macintyre, G. et al. Copy-number signatures and mutational processes in ovarian carcinoma. Nat. Genet. 50, 1262–1270 (2018).
pubmed: 30104763
pmcid: 6130818
doi: 10.1038/s41588-018-0179-8
Iida, Y., Okamoto, A., Hollis, R. L., Gourley, C. & Herrington, C. S. Clear cell carcinoma of the ovary: a clinical and molecular perspective. Int. J. Gynecol. Cancer 31, 605–616 (2021).
pubmed: 32948640
doi: 10.1136/ijgc-2020-001656
Mullen, J., Kato, S., Sicklick, J. K. & Kurzrock, R. Targeting ARID1A mutations in cancer. Cancer Treat. Rev. 100, 102287 (2021).
pubmed: 34619527
doi: 10.1016/j.ctrv.2021.102287
Tsuchiya, A. et al. Expression profiling in ovarian clear cell carcinoma. Am. J. Pathol. 163, 2503–2512 (2003).
pubmed: 14633622
pmcid: 1892387
doi: 10.1016/S0002-9440(10)63605-X
Gadducci, A. & Cosio, S. Therapeutic approach to low-grade serous ovarian carcinoma: state of art and perspectives of clinical research. Cancers 12, 1336 (2020).
pubmed: 32456205
pmcid: 7281204
doi: 10.3390/cancers12051336
Ryland, G. L. et al. Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med. 7, 87 (2015).
pubmed: 26257827
pmcid: 4528310
doi: 10.1186/s13073-015-0210-y
Anglesio, M. S. et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J. Pathol. 229, 111–120 (2013).
pubmed: 22899400
doi: 10.1002/path.4088
Schoutrop, E. et al. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. Semin. Cancer Biol. 86, 207–223 (2022).
pubmed: 35395389
doi: 10.1016/j.semcancer.2022.03.027
Horst, E. N. et al. Personalized models of heterogenous 3d epithelial tumor microenvironments: ovarian cancer as a model. Acta Biomater. 132, 401–420 (2021).
pubmed: 33940195
pmcid: 8969826
doi: 10.1016/j.actbio.2021.04.041
Fucikova, J. et al. Immunological configuration of ovarian carcinoma: features and impact on disease outcome. J. Immunother. Cancer 9, e002873 (2021).
pubmed: 34645669
pmcid: 8515436
doi: 10.1136/jitc-2021-002873
Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).
pubmed: 12529460
doi: 10.1056/NEJMoa020177
Sato, E. et al. Intraepithelial CD8
pubmed: 16344461
pmcid: 1311741
doi: 10.1073/pnas.0509182102
Zou, W. et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 7, 1339–1346 (2001).
pubmed: 11726975
doi: 10.1038/nm1201-1339
Mastelic-Gavillet, B. et al. Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer. Eur. J. Cancer 135, 173–182 (2020).
pubmed: 32590296
doi: 10.1016/j.ejca.2020.04.036
Chen, Y. et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J. Biomed. Sci. 26, 78 (2019).
pubmed: 31629410
pmcid: 6800990
doi: 10.1186/s12929-019-0568-z
Zheng, X. et al. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget 8, 48436–48452 (2017).
pubmed: 28467800
pmcid: 5564660
doi: 10.18632/oncotarget.17061
Schweer, D. et al. Tumor-associated macrophages and ovarian cancer: implications for therapy. Cancers 14, 2220 (2022).
pubmed: 35565348
pmcid: 9101750
doi: 10.3390/cancers14092220
Kandalaft, L. E., Dangaj Laniti, D. & Coukos, G. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat. Rev. Cancer 22, 640–656 (2022).
pubmed: 36109621
doi: 10.1038/s41568-022-00503-z
Zhang, A. W. et al. Interfaces of malignant and immunologic clonal dynamics in ovarian cancer. Cell 173, 1755–1769.e22 (2018).
pubmed: 29754820
doi: 10.1016/j.cell.2018.03.073
Burdett, N. L. et al. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer. Nat. Genet. 55, 437–450 (2023).
pubmed: 36849657
doi: 10.1038/s41588-023-01320-2
Pickup, M. W., Mouw, J. K. & Weaver, V. M. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 15, 1243–1253 (2014).
pubmed: 25381661
pmcid: 4264927
doi: 10.15252/embr.201439246
McPherson, A. et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat. Genet. 48, 758–767 (2016).
pubmed: 27182968
doi: 10.1038/ng.3573
Garsed, D. W. et al. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nat. Genet. 54, 1853–1864 (2022).
pubmed: 36456881
pmcid: 10478425
doi: 10.1038/s41588-022-01230-9
Sioulas, V. D. et al. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy? Gynecol. Oncol. 145, 15–20 (2017).
pubmed: 28238354
pmcid: 5386177
doi: 10.1016/j.ygyno.2017.02.023
Wright, A. A. et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of gynecologic oncology and American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 34, 3460–3473 (2016).
pubmed: 27502591
doi: 10.1200/JCO.2016.68.6907
Straubhar, A., Chi, D. S. & Long Roche, K. Update on the role of surgery in the management of advanced epithelial ovarian cancer. Clin. Adv. Hematol. Oncol. 18, 723–731 (2020).
pubmed: 33406064
Chi, D. S. et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol. Oncol. 103, 559–564 (2006).
pubmed: 16714056
doi: 10.1016/j.ygyno.2006.03.051
Aletti, G. D. et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet. Gynecol. 107, 77–85 (2006).
pubmed: 16394043
doi: 10.1097/01.AOG.0000192407.04428.bb
Winter, W. E. et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25, 3621–3627 (2007).
pubmed: 17704411
doi: 10.1200/JCO.2006.10.2517
Colombo, P.-E. et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur. J. Surg. Oncol. 35, 135–143 (2009).
pubmed: 18289825
doi: 10.1016/j.ejso.2008.01.005
Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416–2428 (2019).
pubmed: 31851799
doi: 10.1056/NEJMoa1911361
Fagotti, A. et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann. Surg. Oncol. 13, 1156–1161 (2006).
pubmed: 16791447
doi: 10.1245/ASO.2006.08.021
Suidan, R. S. et al. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecol. Oncol. 145, 27–31 (2017).
pubmed: 28209497
pmcid: 5387995
doi: 10.1016/j.ygyno.2017.02.020
Reuss, A. et al. TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7). Int. J. Gynecol. Cancer 29, 1327–1331 (2019).
pubmed: 31420412
doi: 10.1136/ijgc-2019-000682
Lv, X., Cui, S., Zhang, X. & Ren, C. Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis. J. Gynecol. Oncol. 31, e12 (2020).
pubmed: 31912670
doi: 10.3802/jgo.2020.31.e12
Mueller, J. J. et al. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol. Oncol. 140, 436–442 (2016).
pubmed: 26777991
pmcid: 4767587
doi: 10.1016/j.ygyno.2016.01.008
Gu, S. et al. Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. Proc. Natl Acad. Sci. USA 118, e2026663118 (2021).
pubmed: 34161278
pmcid: 8237655
doi: 10.1073/pnas.2026663118
Aletti, G. D. et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol. Oncol. 120, 23–28 (2011).
pubmed: 20933255
doi: 10.1016/j.ygyno.2010.09.010
Handley, K. F. et al. Frailty repels the knife: the impact of frailty index on surgical intervention and outcomes. Gynecol. Oncol. 166, 50–56 (2022).
pubmed: 35599168
doi: 10.1016/j.ygyno.2022.05.009
Nelson, G. et al. Guidelines for perioperative care in gynecologic/oncology: enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update. Int. J. Gynecol. Cancer 29, 651–668 (2019).
pubmed: 30877144
doi: 10.1136/ijgc-2019-000356
Miralpeix, E. et al. Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study. World J. Surg. Oncol. 20, 46 (2022).
pubmed: 35197061
pmcid: 8864603
doi: 10.1186/s12957-022-02517-1
Axtell, A. E. et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J. Clin. Oncol. 25, 384–389 (2007).
pubmed: 17264334
doi: 10.1200/JCO.2006.07.7800
Salani, R., Axtell, A., Gerardi, M., Holschneider, C. & Bristow, R. E. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol. Oncol. 108, 271–275 (2008).
pubmed: 18164380
doi: 10.1016/j.ygyno.2007.11.004
Qayyum, A. et al. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol. Oncol. 96, 301–306 (2005).
pubmed: 15661212
doi: 10.1016/j.ygyno.2004.06.054
Risum, S. et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography–a prospective study. Gynecol. Oncol. 108, 265–270 (2008).
pubmed: 18055006
doi: 10.1016/j.ygyno.2007.11.002
Suidan, R. S. et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol. Oncol. 134, 455–461 (2014).
pubmed: 25019568
pmcid: 4387777
doi: 10.1016/j.ygyno.2014.07.002
Riester, M. et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J. Natl Cancer Inst. 106, dju048 (2014).
pubmed: 24700803
pmcid: 4580556
doi: 10.1093/jnci/dju048
Penick, E. R. et al. Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues. Clin. Proteom. 19, 35 (2022).
doi: 10.1186/s12014-022-09372-y
Piedimonte, S. et al. Using a machine learning algorithm to predict outcome of primary cytoreductive surgery in advanced ovarian cancer. J. Surg. Oncol. 127, 465–472 (2023).
pubmed: 36350138
doi: 10.1002/jso.27137
Kawakami, E. et al. Application of artificial intelligence for preoperative diagnostic and prognostic prediction in epithelial ovarian cancer based on blood biomarkers. Clin. Cancer Res. 25, 3006–3015 (2019).
pubmed: 30979733
doi: 10.1158/1078-0432.CCR-18-3378
Piedimonte, S. et al. Evaluating the use of machine learning use in ovarian cancer: a systematic review. J. Clin. Oncol. 40, e17570–e17570 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.e17570
Griffiths, C. T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst. Monogr. 42, 101–104 (1975).
pubmed: 1234624
du Bois, A. et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115, 1234–1244 (2009).
pubmed: 19189349
doi: 10.1002/cncr.24149
Long Roche, K. & Gardner, G. J. State of the science: evolving role of surgery for the treatment of ovarian cancer. Gynecol. Oncol. 155, 3–7 (2019).
pubmed: 31472939
doi: 10.1016/j.ygyno.2019.08.016
Chi, D. S. et al. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol. Oncol. 119, 38–42 (2010).
pubmed: 20609464
doi: 10.1016/j.ygyno.2010.05.031
Tseng, J. H. et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete gross resection rates independently lead to increased progression-free and overall survival? Gynecol. Oncol. 151, 24–31 (2018).
pubmed: 30126704
pmcid: 6247423
doi: 10.1016/j.ygyno.2018.08.014
Harter, P. et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N. Engl. J. Med. 380, 822–832 (2019).
pubmed: 30811909
doi: 10.1056/NEJMoa1808424
Voelker, R. Lighting the way for improved detection of ovarian cancer. JAMA 327, 27 (2022).
pubmed: 34982136
Tanyi, J. L. et al. A phase III study of pafolacianine injection (OTL38) for intraoperative imaging of folate receptor-positive ovarian cancer (Study 006). J. Clin. Oncol. 41, 276–284 (2023).
pubmed: 36070540
doi: 10.1200/JCO.22.00291
Vergote, I. et al. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. Lancet Oncol. 23, e374–e384 (2022).
pubmed: 35901833
pmcid: 9465953
doi: 10.1016/S1470-2045(22)00139-5
Goldberg, R. M. et al. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: a systematic review and meta-analysis. Gynecol. Oncol. 164, 212–220 (2022).
pubmed: 34756470
doi: 10.1016/j.ygyno.2021.10.080
Kurnit, K. C. & Frumovitz, M. Primary mucinous ovarian cancer: options for surgery and chemotherapy. Int. J. Gynecol. Cancer 32, 1455–1462 (2022).
doi: 10.1136/ijgc-2022-003806
Berek, J. S., Hacker, N. F., Lagasse, L. D., Nieberg, R. K. & Elashoff, R. M. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet. Gynecol. 61, 189–193 (1983).
pubmed: 6823360
Al Rawahi, T. et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst. Rev. 2013, CD008765 (2013).
pubmed: 23450588
pmcid: 6457850
Harter, P. et al. Surgery in recurrent ovarian cancer: the arbeitsgemeinschaft gynaekologische onkologie (AGO) desktop ovar trial. Ann. Surg. Oncol. 13, 1702–1710 (2006).
pubmed: 17009163
doi: 10.1245/s10434-006-9058-0
Harter, P. et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO. Int. J. Gynecol. Cancer 21, 289–295 (2011).
pubmed: 21270612
doi: 10.1097/IGC.0b013e31820aaafd
Du Bois, A. et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J. Clin. Oncol. 35, 5501 (2017).
doi: 10.1200/JCO.2017.35.15_suppl.5501
Harter, P. et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N. Engl. J. Med. 385, 2123–2131 (2021).
pubmed: 34874631
doi: 10.1056/NEJMoa2103294
Coleman, R. L. et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N. Engl. J. Med. 381, 1929–1939 (2019).
pubmed: 31722153
pmcid: 6941470
doi: 10.1056/NEJMoa1902626
Shi, T. et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 22, 439–449 (2021).
pubmed: 33705695
doi: 10.1016/S1470-2045(21)00006-1
Cowan, R. A. et al. A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer. Gynecol. Oncol. 145, 230–235 (2017).
pubmed: 28285846
doi: 10.1016/j.ygyno.2017.02.010
Janco, J. M. T., Kumar, A., Weaver, A. L., McGree, M. E. & Cliby, W. A. Performance of AGO score for secondary cytoreduction in a high-volume U.S. center. Gynecol. Oncol. 141, 140–147 (2016).
pubmed: 26836496
doi: 10.1016/j.ygyno.2016.01.027
Lambert, H. E. & Berry, R. J. High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group. Br. Med. J. 290, 889–893 (1985).
doi: 10.1136/bmj.290.6472.889
Katsumata, N. et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet Lond. Engl. 374, 1331–1338 (2009).
doi: 10.1016/S0140-6736(09)61157-0
Katsumata, N. et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 14, 1020–1026 (2013).
pubmed: 23948349
doi: 10.1016/S1470-2045(13)70363-2
Chan, J. K. et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N. Engl. J. Med. 374, 738–748 (2016).
pubmed: 26933849
pmcid: 5081077
doi: 10.1056/NEJMoa1505067
Pignata, S. et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 15, 396–405 (2014).
pubmed: 24582486
doi: 10.1016/S1470-2045(14)70049-X
Clamp, A. R. et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet Lond. Engl. 394, 2084–2095 (2019).
doi: 10.1016/S0140-6736(19)32259-7
Clamp, A. R. et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 23, 919–930 (2022).
pubmed: 35690073
pmcid: 9630160
doi: 10.1016/S1470-2045(22)00283-2
Marchetti, C., Muzii, L., Romito, A. & Benedetti Panici, P. First-line treatment of women with advanced ovarian cancer: focus on bevacizumab. Onco Targets Ther. 12, 1095–1103 (2019).
pubmed: 30799939
pmcid: 6371937
doi: 10.2147/OTT.S155425
Burger, R. A. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473–2483 (2011).
pubmed: 22204724
doi: 10.1056/NEJMoa1104390
Perren, T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484–2496 (2011).
pubmed: 22204725
doi: 10.1056/NEJMoa1103799
Tewari, K. S. et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J. Clin. Oncol. 37, 2317–2328 (2019).
pubmed: 31216226
pmcid: 6879307
doi: 10.1200/JCO.19.01009
Pfisterer, J. et al. Optimal treatment duration of bevacizumab as front-line therapy for advanced ovarian cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 open-label randomized phase III trial. J. Clin. Oncol. 41, 893–902 (2023).
pubmed: 36332161
doi: 10.1200/JCO.22.01010
Norquist, B. M. et al. Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study. Clin. Cancer Res. 24, 777–783 (2018).
pubmed: 29191972
doi: 10.1158/1078-0432.CCR-17-1327
Maru, D., Venook, A. P. & Ellis, L. M. Predictive biomarkers for bevacizumab: are we there yet? Clin. Cancer Res. 19, 2824–2827 (2013).
pubmed: 23549876
doi: 10.1158/1078-0432.CCR-12-3409
Alberts, D. S. et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335, 1950–1955 (1996).
pubmed: 8960474
doi: 10.1056/NEJM199612263352603
Markman, M. et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19, 1001–1007 (2001).
pubmed: 11181662
doi: 10.1200/JCO.2001.19.4.1001
Tewari, D. et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 33, 1460–1466 (2015).
pubmed: 25800756
pmcid: 4404424
doi: 10.1200/JCO.2014.55.9898
Wenzel, L. B. et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25, 437–443 (2007).
pubmed: 17264340
doi: 10.1200/JCO.2006.07.3494
Walker, J. L. et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group Study. J. Clin. Oncol. 37, 1380–1390 (2019).
pubmed: 31002578
pmcid: 6544459
doi: 10.1200/JCO.18.01568
Provencher, D. M. et al. OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. Ann. Oncol. 29, 431–438 (2018).
pubmed: 29186319
doi: 10.1093/annonc/mdx754
Nagao, S. et al. Intraperitoneal carboplatin for ovarian cancer — a phase 2/3 trial. NEJM Evid. 2, EVIDoa2200225 (2023).
doi: 10.1056/EVIDoa2200225
Schwameis, R., Chiva, L. & Harter, P. There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Int. J. Gynecol. Cancer 32, 578 (2022).
pubmed: 35121632
doi: 10.1136/ijgc-2022-003348
van Driel, W. J. et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N. Engl. J. Med. 378, 230–240 (2018).
pubmed: 29342393
doi: 10.1056/NEJMoa1708618
Lim, P.-Q., Han, I.-H., Seow, K.-M. & Chen, K.-H. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): an overview of the molecular and cellular mechanisms of actions and effects on epithelial ovarian cancers. Int. J. Mol. Sci. 23, 10078 (2022).
pubmed: 36077477
pmcid: 9456527
doi: 10.3390/ijms231710078
Zivanovic, O. et al. Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK Team Ovary Phase II Study. J. Clin. Oncol. 39, 2594–2604 (2021).
pubmed: 34019431
pmcid: 8330970
doi: 10.1200/JCO.21.00605
Chiva, L. M. & Gonzalez-Martin, A. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecol. Oncol. 136, 130–135 (2015).
pubmed: 25434634
doi: 10.1016/j.ygyno.2014.11.072
McMullen, M., Karakasis, K., Madariaga, A. & Oza, A. M. Overcoming platinum and PARP-inhibitor resistance in ovarian cancer. Cancers 12, 1607 (2020).
pubmed: 32560564
pmcid: 7352566
doi: 10.3390/cancers12061607
Pennington, K. P. et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 20, 764–775 (2014).
pubmed: 24240112
doi: 10.1158/1078-0432.CCR-13-2287
DiSilvestro, P. et al. Overall survival with maintenance olaparib at a 7-Year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J. Clin. Oncol. 41, 609–617 (2023).
pubmed: 36082969
doi: 10.1200/JCO.22.01549
González-Martín, A. et al. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur. J. Cancer 189, 112908 (2023).
pubmed: 37263896
doi: 10.1016/j.ejca.2023.04.024
Monk, B. J. et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J. Clin. Oncol. 40, 3952–3964 (2022).
pubmed: 35658487
pmcid: 9746782
doi: 10.1200/JCO.22.01003
Coleman, R. L. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond. Engl. 390, 1949–1961 (2017).
doi: 10.1016/S0140-6736(17)32440-6
Ray-Coquard, I. et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann. Oncol. 34, 681–692 (2023).
pubmed: 37211045
doi: 10.1016/j.annonc.2023.05.005
Loverix, L. et al. Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6). Gynecol. Oncol. 166, S51–S52 (2022).
doi: 10.1016/S0090-8258(22)01299-9
Watkins, J. A., Irshad, S., Grigoriadis, A. & Tutt, A. N. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 16, 211 (2014).
pubmed: 25093514
pmcid: 4053155
doi: 10.1186/bcr3670
González-Martín, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391–2402 (2019).
pubmed: 31562799
doi: 10.1056/NEJMoa1910962
Hodgson, D. R. et al. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. Br. J. Cancer 119, 1401–1409 (2018).
pubmed: 30353044
pmcid: 6265286
doi: 10.1038/s41416-018-0274-8
Banerjee, S. et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 1721–1731 (2021).
pubmed: 34715071
doi: 10.1016/S1470-2045(21)00531-3
Tew, W. P. et al. PARP inhibitors in the management of ovarian cancer: ASCO guideline. J. Clin. Oncol. 38, 3468–3493 (2020).
pubmed: 32790492
doi: 10.1200/JCO.20.01924
Mirza, M. R. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375, 2154–2164 (2016).
pubmed: 27717299
doi: 10.1056/NEJMoa1611310
Tattersall, A., Ryan, N., Wiggans, A. J., Rogozińska, E. & Morrison, J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst. Rev. 2, CD007929 (2022).
pubmed: 35170751
Oza, A. M. et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 16, 87–97 (2015).
pubmed: 25481791
doi: 10.1016/S1470-2045(14)71135-0
Yap, T. A. et al. Phase I trial of the PARP inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2- and non-BRCA1/2-mutant cancers. Cancer Discov. 10, 1528–1543 (2020).
pubmed: 32532747
pmcid: 7611385
doi: 10.1158/2159-8290.CD-20-0163
Sun, C. et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci. Transl. Med. 9, eaal5148 (2017).
pubmed: 28566428
pmcid: 5919217
doi: 10.1126/scitranslmed.aal5148
Westin, S. et al. SOLAR: phase Ib dose expansion of selumetinib (MEK inhibitor) and OLAparib (PARP inhibitor) combination in solid tumors with RAS pathway alterations and in PARP inhibitor-resistant ovarian cancer (LBA 9). Gynecol. Oncol. 176, S33 (2023).
doi: 10.1016/j.ygyno.2023.06.511
Yap, T. A. et al. Abstract CT030: genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-related inhibitor (ATRi), in patients (pts) with DNA damage repair (DDR) loss-of-function (LOF) mutant tumors in the phase 1/2 TRESR trial. Cancer Res. 82, CT030 (2022).
doi: 10.1158/1538-7445.AM2022-CT030
Shima, N., Munroe, R. J. & Schimenti, J. C. The mouse genomic instability mutation chaos1 is an allele of Polq that exhibits genetic interaction with Atm. Mol. Cell. Biol. 24, 10381–10389 (2004).
pubmed: 15542845
pmcid: 529050
doi: 10.1128/MCB.24.23.10381-10389.2004
Wyatt, D. W. et al. Essential roles for polymerase θ-mediated end joining in the repair of chromosome breaks. Mol. Cell 63, 662–673 (2016).
pubmed: 27453047
pmcid: 4992412
doi: 10.1016/j.molcel.2016.06.020
Zhou, J. et al. A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors. Nat. Cancer 2, 598–610 (2021).
pubmed: 34179826
pmcid: 8224818
doi: 10.1038/s43018-021-00203-x
Zatreanu, D. et al. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nat. Commun. 12, 3636 (2021).
pubmed: 34140467
pmcid: 8211653
doi: 10.1038/s41467-021-23463-8
Rodriguez-Berriguete, G. et al. Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models. Clin. Cancer Res. 29, 1631–1642 (2023).
pubmed: 36689546
pmcid: 10102842
doi: 10.1158/1078-0432.CCR-22-2977
Hwang, W.-T., Adams, S. F., Tahirovic, E., Hagemann, I. S. & Coukos, G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol. Oncol. 124, 192–198 (2012).
pubmed: 22040834
doi: 10.1016/j.ygyno.2011.09.039
Ni, Y. et al. The role of tumor-stroma interactions in drug resistance within tumor microenvironment. Front. Cell Dev. Biol. 9, 637675 (2021).
pubmed: 34095111
pmcid: 8173135
doi: 10.3389/fcell.2021.637675
Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).
pubmed: 28420421
pmcid: 5395719
doi: 10.1186/s13073-017-0424-2
Matulonis, U. A. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol. 30, 1080–1087 (2019).
pubmed: 31046082
doi: 10.1093/annonc/mdz135
Pal, T., Permuth-Wey, J., Kumar, A. & Sellers, T. A. Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clin. Cancer Res. 14, 6847–6854 (2008).
pubmed: 18980979
pmcid: 2655731
doi: 10.1158/1078-0432.CCR-08-1387
Germano, G. et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552, 116–120 (2017).
pubmed: 29186113
doi: 10.1038/nature24673
Shakfa, N., Li, D., Nersesian, S., Wilson-Sanchez, J. & Koti, M. The STING pathway: therapeutic vulnerabilities in ovarian cancer. Br. J. Cancer 127, 603–611 (2022).
pubmed: 35383278
pmcid: 9381712
doi: 10.1038/s41416-022-01797-4
Shen, J. et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 79, 311–319 (2019).
pubmed: 30482774
doi: 10.1158/0008-5472.CAN-18-1003
Higuchi, T. et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol. Res. 3, 1257–1268 (2015).
pubmed: 26138335
pmcid: 4984269
doi: 10.1158/2326-6066.CIR-15-0044
Wang, Z. et al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci. Rep. 9, 1853 (2019).
pubmed: 30755715
pmcid: 6372650
doi: 10.1038/s41598-019-38534-6
Appleton, K. M. et al. PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures. Cancer Immunol. Immunother. 70, 843–856 (2021).
pubmed: 33492447
doi: 10.1007/s00262-021-02849-z
Lampert, E. J. et al. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study. Clin. Cancer Res. 26, 4268–4279 (2020).
pubmed: 32398324
pmcid: 7442720
doi: 10.1158/1078-0432.CCR-20-0056
Kroon, P. et al. Radiotherapy and cisplatin increase immunotherapy efficacy by enabling local and systemic intratumoral T-cell activity. Cancer Immunol. Res. 7, 670–682 (2019).
pubmed: 30782666
doi: 10.1158/2326-6066.CIR-18-0654
Zhang, Z., Yu, X., Wang, Z., Wu, P. & Huang, J. Anthracyclines potentiate anti-tumor immunity: a new opportunity for chemoimmunotherapy. Cancer Lett. 369, 331–335 (2015).
pubmed: 26454214
doi: 10.1016/j.canlet.2015.10.002
Zitvogel, L., Apetoh, L., Ghiringhelli, F. & Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59–73 (2008).
pubmed: 18097448
doi: 10.1038/nri2216
Färkkilä, A. et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat. Commun. 11, 1459 (2020).
pubmed: 32193378
pmcid: 7081234
doi: 10.1038/s41467-020-15315-8
Pujade-Lauraine, E., Fujiwara, K., Dychter, S. S., Devgan, G. & Monk, B. J. Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 phase III study design. Future Oncol. Lond. Engl. 14, 2103–2113 (2018).
doi: 10.2217/fon-2018-0070
Moore, K. N. et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39). J. Clin. Oncol. 39, 1842–1855 (2021).
pubmed: 33891472
pmcid: 8189598
doi: 10.1200/JCO.21.00306
Ghiringhelli, F. et al. Metronomic cyclophosphamide regimen selectively depletes CD4
pubmed: 16960692
doi: 10.1007/s00262-006-0225-8
Weir, G. M. et al. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. Oncoimmunology 3, e953407 (2014).
pubmed: 25960932
pmcid: 4368141
doi: 10.4161/21624011.2014.953407
Santillan, A. et al. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. Int. J. Gynecol. Cancer 17, 601–606 (2007).
pubmed: 17504374
doi: 10.1111/j.1525-1438.2007.00820.x
Schmeler, K. M. et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol. Oncol. 108, 510–514 (2008).
pubmed: 18155273
doi: 10.1016/j.ygyno.2007.11.013
Nickles Fader, A., Gien, L. T., Miller, A., Covens, A. & Gershenson, D. M. A randomized phase III, two-arm trial of paclitaxel, carboplatin, and maintenance letrozole versus letrozole monotherapy in patients with stage II-IV, primary low-grade serous carcinoma of the ovary or peritoneum. J. Clin. Oncol. 39, TPS5601 (2021).
doi: 10.1200/JCO.2021.39.15_suppl.TPS5601
Dalton, H. J. et al. Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: a single institution experience. Gynecol. Oncol. 145, 37–40 (2017).
pubmed: 28139261
pmcid: 5884069
doi: 10.1016/j.ygyno.2017.01.027
Monk, B. J. et al. MILO/ENGOT-ov11: binimetinib versus physician’s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. J. Clin. Oncol. 38, 3753–3762 (2020).
pubmed: 32822286
pmcid: 7655017
doi: 10.1200/JCO.20.01164
Gershenson, D. M. et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet Lond. Engl. 399, 541–553 (2022).
doi: 10.1016/S0140-6736(21)02175-9
Shrestha, R. et al. Multiomics characterization of low-grade serous ovarian carcinoma identifies potential biomarkers of MEK inhibitor sensitivity and therapeutic vulnerability. Cancer Res. 81, 1681–1694 (2021).
pubmed: 33441310
doi: 10.1158/0008-5472.CAN-20-2222
Banerjee, S. N. et al. ENGOT-ov60/GOG-3052/RAMP 201: a phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC). J. Clin. Oncol. 40, TPS5615 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.TPS5615
Business Wire. Verastem Oncology announces design for confirmatory trial of avutometinib and defactinib in recurrent low-grade serous ovarian cancer. https://www.businesswire.com/news/home/20230705791373/en/Verastem-Oncology-Announces-Design-for-Confirmatory-Trial-of-Avutometinib-and-Defactinib-in-Recurrent-Low-Grade-Serous-Ovarian-Cancer (2023).
Seki, T. et al. Bevacizumab in first-line chemotherapy to improve the survival outcome for advanced ovarian clear cell carcinoma: a multicenter, retrospective analysis. J. Clin. Oncol. 40, 5502–5502 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.5502
Hogen, L. et al. The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma. Gynecol. Oncol. 143, 258–263 (2016).
pubmed: 27623251
doi: 10.1016/j.ygyno.2016.09.006
Pautier, P. et al. Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type. Ann. Oncol. 18, 1985–1989 (2007).
pubmed: 17761699
doi: 10.1093/annonc/mdm376
Blanc, F. et al. Effect of high-dose chemotherapy with autologous stem cell rescue (HDC-aSCR) on outcome in ovarian small-cell carcinoma, hypercalcemic type (SCCOHT): prospective series from the French Rare Gynecologic Malignant Tumors Network (TMRG). J. Clin. Oncol. 38, 6023 (2020).
doi: 10.1200/JCO.2020.38.15_suppl.6023
Wang, Y. et al. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. J. Pathol. 242, 371–383 (2017).
pubmed: 28444909
pmcid: 6857704
doi: 10.1002/path.4912
Xue, Y. et al. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nat. Commun. 10, 558 (2019).
pubmed: 30718512
pmcid: 6361890
doi: 10.1038/s41467-018-06958-9
Zhu, X. et al. Alanine supplementation exploits glutamine dependency induced by SMARCA4/2-loss. Nat. Commun. 14, 2894 (2023).
pubmed: 37210563
pmcid: 10199906
doi: 10.1038/s41467-023-38594-3
Hardy-Bessard, A.-C. et al. ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC). J. Clin. Oncol. 37, TPS5600 (2019).
doi: 10.1200/JCO.2019.37.15_suppl.TPS5600
Ledermann, J. A. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24, vi24–vi32 (2013).
pubmed: 24078660
doi: 10.1093/annonc/mdt333
Tomao, F., D’Incalci, M., Biagioli, E., Peccatori, F. A. & Colombo, N. Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: myth or reality? Cancer 123, 3450–3459 (2017).
pubmed: 28678350
doi: 10.1002/cncr.30830
Stuart, G. C. E. et al. Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference. Int. J. Gynecol. Cancer 21, 750–755 (2011).
pubmed: 21543936
doi: 10.1097/IGC.0b013e31821b2568
Parmar, M. K. B. et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet Lond. Engl. 361, 2099–2106 (2003).
doi: 10.1016/S0140-6736(03)13718-X
Pfisterer, J. et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24, 4699–4707 (2016).
doi: 10.1200/JCO.2006.06.0913
Wagner, U. et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br. J. Cancer 107, 588–591 (2012).
pubmed: 22836511
pmcid: 3419956
doi: 10.1038/bjc.2012.307
Pujade-Lauraine, E. et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28, 3323–3329 (2010).
pubmed: 20498395
doi: 10.1200/JCO.2009.25.7519
Aghajanian, C. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 30, 2039–2045 (2012).
pubmed: 22529265
pmcid: 3646321
doi: 10.1200/JCO.2012.42.0505
Coleman, R. L. et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 18, 779–791 (2017).
pubmed: 28438473
pmcid: 5715461
doi: 10.1016/S1470-2045(17)30279-6
Pignata, S. et al. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 22, 267–276 (2021).
pubmed: 33539744
doi: 10.1016/S1470-2045(20)30637-9
Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).
pubmed: 19553641
doi: 10.1056/NEJMoa0900212
Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382–1392 (2012).
pubmed: 22452356
doi: 10.1056/NEJMoa1105535
Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274–1284 (2017).
pubmed: 28754483
doi: 10.1016/S1470-2045(17)30469-2
Poveda, A. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 620–631 (2021).
pubmed: 33743851
doi: 10.1016/S1470-2045(21)00073-5
Pujade-Lauraine, E. et al. LBA33. Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): phase IIIb OReO/ENGOT Ov-38 trial. Ann. Oncol. 32, S1308–S1309 (2021).
doi: 10.1016/j.annonc.2021.08.2110
Lheureux, S. et al. EVOLVE: a multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression. Clin. Cancer Res. 26, 4206–4215 (2020).
pubmed: 32444417
doi: 10.1158/1078-0432.CCR-19-4121
Colombo, N. et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann. Oncol. 30, 672–705 (2019).
pubmed: 31046081
doi: 10.1093/annonc/mdz062
Pujade-Lauraine, E. et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. 32, 1302–1308 (2014).
pubmed: 24637997
doi: 10.1200/JCO.2013.51.4489
Coelho, R. et al. Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer. Cell Death Dis. 13, 909 (2022).
pubmed: 36307400
pmcid: 9616819
doi: 10.1038/s41419-022-05347-x
Paracchini, L. et al. Targeted mutational analysis of circulating tumor DNA to decipher temporal heterogeneity of high-grade serous ovarian cancer. Cancers 14, 3697 (2022).
pubmed: 35954363
pmcid: 9367609
doi: 10.3390/cancers14153697
Martin, L. P. et al. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol. Oncol. 147, 402–407 (2017).
pubmed: 28843653
pmcid: 6893864
doi: 10.1016/j.ygyno.2017.08.015
Kalli, K. R. et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol. Oncol. 108, 619–626 (2008).
pubmed: 18222534
pmcid: 2707764
doi: 10.1016/j.ygyno.2007.11.020
Ab, O. et al. IMGN853, a folate receptor-α (FRα)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against frα-expressing tumors. Mol. Cancer Ther. 14, 1605–1613 (2015).
pubmed: 25904506
doi: 10.1158/1535-7163.MCT-14-1095
Matulonis, U. A. et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J. Clin. Oncol. 41, 2436–2445 (2023).
pubmed: 36716407
pmcid: 10150846
doi: 10.1200/JCO.22.01900
Moore, K. N. et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann. Oncol. 32, 757–765 (2021).
pubmed: 33667670
doi: 10.1016/j.annonc.2021.02.017
Moore, K. N. et al. Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. J. Clin. Oncol. 41 (Suppl. 17), LBA5507 (2023).
doi: 10.1200/JCO.2023.41.17_suppl.LBA5507
Konstantinopoulos, P. A. et al. TOPACIO/Keynote-162 (NCT02657889): a phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort. J. Clin. Oncol. 36, 106 (2018).
doi: 10.1200/JCO.2018.36.15_suppl.106
Banerjee, S. et al. 529MO. Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer. Ann. Oncol. 33, S788–S789 (2022).
doi: 10.1016/j.annonc.2022.07.657
Dorigo, O. et al. Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase II trial. Clin. Cancer Res. 29, 2808–2815 (2023).
pubmed: 37126016
pmcid: 10390884
doi: 10.1158/1078-0432.CCR-22-2595
Veneziani, A. et al. Pembrolizumab, maveropepimut-S, and low-dose cyclophosphamide in advanced epithelial ovarian cancer: results from phase 1 and expansion cohort of PESCO trial. J. Clin. Oncol. 40, 5505 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.5505
Moore, K. N. et al. First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer. J. Clin. Oncol. 41, TPS5624 (2023).
doi: 10.1200/JCO.2023.41.16_suppl.TPS5624
Lheureux, S. et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397, 281–292 (2021).
pubmed: 33485453
doi: 10.1016/S0140-6736(20)32554-X
McGee, J. et al. Fifth ovarian cancer consensus conference: individualized therapy and patient factors. Ann. Oncol. 28, 702–710 (2017).
pubmed: 28119296
doi: 10.1093/annonc/mdx010
Madariaga, A. et al. Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma. Gynecol. Oncol. 167, 226–233 (2022).
pubmed: 36055813
doi: 10.1016/j.ygyno.2022.08.006
Wenzel, L. et al. Quality of life and adverse events: prognostic relationships in long-term ovarian cancer survival. J. Natl Cancer Inst. 113, 1369–1378 (2021).
pubmed: 33729494
pmcid: 8486331
doi: 10.1093/jnci/djab034
Madariaga, A., Bowering, V., Ahrari, S., Oza, A. M. & Lheureux, S. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int. J. Gynecol. Cancer 30, 903–915 (2020).
pubmed: 32276934
pmcid: 7398227
doi: 10.1136/ijgc-2020-001288
Friedlander, M. et al. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncol. 22, 632–642 (2021).
pubmed: 33862001
doi: 10.1016/S1470-2045(21)00098-X
Friedlander, M. et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol. 19, 1126–1134 (2018).
pubmed: 30026002
pmcid: 7869962
doi: 10.1016/S1470-2045(18)30343-7
Lee, Y. C. et al. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study. Int. J. Gynecol. Cancer 32, 761–768 (2022).
pubmed: 35086926
pmcid: 9185817
doi: 10.1136/ijgc-2021-003142
Basch, E. et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318, 197–198 (2017).
pubmed: 28586821
pmcid: 5817466
doi: 10.1001/jama.2017.7156
Donovan, H. S. et al. Effects of the WRITE Symptoms Interventions on symptoms and quality of life among patients with recurrent ovarian cancers: an NRG Oncology/GOG Study (GOG-0259). J. Clin. Oncol. 40, 1464–1473 (2022).
pubmed: 35130043
pmcid: 9061156
doi: 10.1200/JCO.21.00656
Herzog, T. J. et al. ARTISTRY-7: a phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68). J. Clin. Oncol. 41, TPS5612 (2023).
doi: 10.1200/JCO.2023.41.16_suppl.TPS5612
Tobalina, L., Armenia, J., Irving, E., O’Connor, M. J. & Forment, J. V. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. Ann. Oncol. 32, 103–112 (2021).
pubmed: 33091561
doi: 10.1016/j.annonc.2020.10.470
Fu, S. et al. 562TiP. A phase Ib dose-escalation study of ZN-c3, a WEE1 inhibitor, in combination with chemotherapy in patients with platinum-resistant or -refractory ovarian, peritoneal, or fallopian tube cancer. Ann. Oncol. 32, S618 (2021).
doi: 10.1016/j.annonc.2021.08.1084
Konstantinopoulos, P. A. et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 21, 957–968 (2020).
pubmed: 32553118
pmcid: 8023719
doi: 10.1016/S1470-2045(20)30180-7
Ngoi, N. Y. L., Leo, E., O’Connor, M. J. & Yap, T. A. Development of next-generation poly(ADP-ribose) polymerase 1-selective inhibitors. Cancer J. Sudbury Mass. 27, 521–528 (2021).
doi: 10.1097/PPO.0000000000000556
Hou, J. Y. et al. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Gynecol. Oncol. 167, 334–341 (2022).
pubmed: 36117009
doi: 10.1016/j.ygyno.2022.09.004
Ovarian, fallopian tube, and peritoneal cancer - statistics. Cancer.Net https://www.cancer.net/cancer-types/ovarian-fallopian-tube-and-peritoneal-cancer/statistics (2012).
Momenimovahed, Z., Tiznobaik, A., Taheri, S. & Salehiniya, H. Ovarian cancer in the world: epidemiology and risk factors. Int. J. Women’s Health 11, 287 (2019).
doi: 10.2147/IJWH.S197604
Walsh, T. et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc. Natl Acad. Sci. USA 108, 18032–18037 (2011).
pubmed: 22006311
pmcid: 3207658
doi: 10.1073/pnas.1115052108
Brundage, M. et al. Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial. Ann. Oncol. 23, 2020–2027 (2012).
pubmed: 22291207
doi: 10.1093/annonc/mdr583
Gordon, A. N. et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19, 3312–3322 (2001).
pubmed: 11454878
doi: 10.1200/JCO.2001.19.14.3312
Monk, B. J. et al. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group. Study. Gynecol. Oncol. 128, 573–578 (2013).
pubmed: 23219660
doi: 10.1016/j.ygyno.2012.11.038
Stark, D. et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 14, 236–243 (2013).
pubmed: 23333117
pmcid: 3596061
doi: 10.1016/S1470-2045(12)70567-3
Stockler, M. R. et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J. Clin. Oncol. 32, 1309–1316 (2014).
pubmed: 24687829
pmcid: 4876313
doi: 10.1200/JCO.2013.51.4240
Barretina-Ginesta, M.-P. et al. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial. Ther. Adv. Med. Oncol. 14, 17588359221126148 (2022).
doi: 10.1177/17588359221126149
Vergote, I. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363, 943–953 (2010).
pubmed: 20818904
doi: 10.1056/NEJMoa0908806
Joly, F. et al. Time without symptoms or toxicity (TWiST) in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib or placebo plus bevacizumab: analysis of PAOLA-1/ENGOT-ov25 phase III trial. J. Clin. Oncol. 40, 5562 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.5562
Aoki, D. & Chiyoda, T. PARP inhibitors and quality of life in ovarian cancer. Lancet Oncol. 19, 1012–1014 (2018).
pubmed: 30026001
doi: 10.1016/S1470-2045(18)30435-2
Matulonis, U. A. et al. Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA trial. J. Clin. Oncol. 37, 3183–3191 (2019).
pubmed: 31518175
pmcid: 6881097
doi: 10.1200/JCO.19.00917
Oza, A. M. et al. Patient-centered outcomes in ARIEL3, a phase III, randomized, placebo-controlled trial of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma. J. Clin. Oncol. 38, 3494–3505 (2020).
pubmed: 32840418
pmcid: 7571791
doi: 10.1200/JCO.19.03107
Madariaga, A., Rustin, G. J. S., Buckanovich, R. J., Trent, J. C. & Oza, A. M. Wanna get away? maintenance treatments and chemotherapy holidays in gynecologic cancers. Am. Soc. Clin. Oncol. 39, e152–e166 (2019).
Ortiz, M., Wabel, E., Mitchell, K. & Horibata, S. Mechanisms of chemotherapy resistance in ovarian cancer. Cancer Drug Resist. 5, 306–316 (2022).
Alatise, K. L., Gardner, S. & Alexander-Bryant, A. Mechanisms of drug resistance in ovarian cancer and associated gene targets. Cancers 14, 6246 (2022).
pubmed: 36551731
pmcid: 9777152
doi: 10.3390/cancers14246246
Szymczyk, J. et al. FGF/FGFR-dependent molecular mechanisms underlying anti-cancer drug resistance. Cancers 13, 5796 (2021).
pubmed: 34830951
pmcid: 8616288
doi: 10.3390/cancers13225796